HIV resistance to nucleoside analogues such as zidovudine (AZT) is to date a source of concern, even if its clinical significance is yet to be determined. Phenotypic and genotypic data concerning HIV resistance will be presented, then the potential benefits of nucleoside combinations will be discussed.